ctDNA as a Biomarker for Treatment in Advanced NSCLC

ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC

NCT05198154 ·Status: RECRUITING

ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS

NCT03172156 ·Status: COMPLETED

Multiplex Analysis of Circulating Tumor DNA

NCT03301961 ·Status: UNKNOWN

Evaluation ctDNA in Patients of Non-Small-Cell Lung Cancer Following Resection

NCT04238130 ·Status: COMPLETED

Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan

NCT06358222 ·Status: RECRUITING

Biomarkers of Stage III Locally Advanced Unresectable Non-small-cell Lung Cancer

NCT04749407 ·Status: UNKNOWN

DNA Methylation Biomarkers to Predict Survival After Surgery for Lung Adenocarcinoma

NCT06477211 ·Status: COMPLETED

Comparison of Circulating Tumor DNA and Tumor Tissue DNA by Targeted Sequencing in Non-Small Cell Lung Cancer

NCT02645318 ·Status: COMPLETED

Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients

NCT02696525 ·Status: UNKNOWN

NGS-based Comprehensive Genomic ctDNA Panel in NSCLC With Immunotherapy

NCT04636047 ·Status: UNKNOWN

Biomarkers for Diagnosis of Lung Cancer

NCT02050100 ·Status: COMPLETED

The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer

NCT06287320 ·Status: RECRUITING

Non-Invasive ctDNA Methylation Detection for Lung Nodule Patients

NCT03685669 ·Status: UNKNOWN

Circulating Tumor DNA Methylation Test to Differentiate Benign and Malignant Pulmonary Nodules

NCT03181490 ·Status: COMPLETED

MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC

NCT06198868 ·Status: RECRUITING

Circulating Immune Markers for Prognostic Evaluation in Postoperative Lung Cancer Patients

NCT07242482 ·Status: NOT_YET_RECRUITING

Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA

NCT03926260 ·Status: COMPLETED ·Phase: NA

irAE Prediction of Anti-PD-1/L1 in Lung Cancer

NCT05288569 ·Status: UNKNOWN

Circulating Tumor DNA in Surgical Lung Cancer Patients

NCT03081741 ·Status: UNKNOWN

ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage II to IIIA NSCLC by NGS

NCT03465241 ·Status: COMPLETED

Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients

NCT02804100 ·Status: UNKNOWN

Chromosomal Instability as a Surrogate Biomarker of Drug Resistance in Immunotherapy for Lung Cancer Patients

NCT04203095 ·Status: UNKNOWN

Liquid Biopsy in Advanced Oligometastatic NSCLC Receiving Surgery

NCT05648370 ·Status: UNKNOWN

Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC.

NCT06167460 ·Status: RECRUITING

Monitoring the Changes of Tumor-related Biomarkers Before and After Pulmonary Nodule Biopsy.

NCT03397355 ·Status: UNKNOWN